title: Transgenic overexpression of cardiac A(1) adenosine receptors mimics ischemic preconditioning.
abstract: The role of A(1) adenosine receptors (A(1)AR) in ischemic preconditioning was investigated in isolated crystalloid-perfused wild-type and transgenic mouse hearts with increased A(1)AR. The effect of preconditioning on postischemic myocardial function, lactate dehydrogenase (LDH) release, and infarct size was examined. Functional recovery was greater in transgenic versus wild-type hearts (44.8 +/- 3.4% baseline vs. 25.6 +/- 1.7%). Preconditioning improved functional recovery in wild-type hearts from 25.6 +/- 1.7% to 37.4 +/- 2.2% but did not change recovery in transgenic hearts (44.8 +/- 3.4% vs. 44.5 +/- 3.9%). In isovolumically contracting hearts, pretreatment with selective A(1) receptor antagonist 1, 3-dipropyl-8-cyclopentylxanthine attenuated the improved functional recovery in both wild-type preconditioned (74.2 +/- 7.3% baseline rate of pressure development over time untreated vs. 29.7 +/- 7.3% treated) and transgenic hearts (84.1 +/- 12.8% untreated vs. 42.1 +/- 6.8% treated). Preconditioning wild-type hearts reduced LDH release (from 7,012 +/- 1,451 to 1,691 +/- 1,256 U. l(-1). g(-1). min(-1)) and infarct size (from 62.6 +/- 5.1% to 32.3 +/- 11.5%). Preconditioning did not affect LDH release or infarct size in hearts overexpressing A(1)AR. Compared with wild-type hearts, A(1)AR overexpression markedly reduced LDH release (from 7,012 +/- 1,451 to 917 +/- 1,123 U. l(-1). g(-1). min(-1)) and infarct size (from 62.6 +/- 5.1% to 6.5 +/- 2.1%). These data demonstrate that murine preconditioning involves endogenous activation of A(1)AR. The beneficial effects of preconditioning and A(1)AR overexpression are not additive. Taken with the observation that A(1)AR blockade equally eliminates the functional protection resulting from both preconditioning and transgenic A(1)AR overexpression, we conclude that the two interventions affect cardioprotection via common mechanisms or pathways.
authors.affiliation: Department of Pediatrics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.
authors.forename: R R
authors.initials: RR
authors.lastname: Morrison
authors.forename: R
authors.initials: R
authors.lastname: Jones
authors.forename: A M
authors.initials: AM
authors.lastname: Byford
authors.forename: A R
authors.initials: AR
authors.lastname: Stell
authors.forename: J
authors.initials: J
authors.lastname: Peart
authors.forename: J P
authors.initials: JP
authors.lastname: Headrick
authors.forename: G P
authors.initials: GP
authors.lastname: Matherne
mesh_terms: D000818:Animals; D001783:Blood Flow Velocity; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D004396:Coloring Agents; D003326:Coronary Circulation; D066298:In Vitro Techniques; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009203:Myocardial Infarction / Q000235:genetics / Q000473:pathology; D017202:Myocardial Ischemia / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1 / Q000096:biosynthesis* / Q000235:genetics*; D020127:Recovery of Function / Q000187:drug effects / Q000235:genetics; D015424:Reperfusion; D014970:Xanthines / Q000494:pharmacology
chemical_list: D004396:Coloring Agents; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; D014970:Xanthines; C051360:1,3-dipropyl-8-cyclopentylxanthine; D007770:L-Lactate Dehydrogenase